Das A M, Naim H Y
Department of Pediatrics, Hannover Medical School, Hannover, Germany
Adv Clin Chem. 2009;49:57-71. doi: 10.1016/s0065-2423(09)49003-6.
Fabry disease, also known as Anderson-Fabry disease, is an X-linked lysosomal storage disorder. The clinical picture is highly variable and usually milder in females. It is a multisystemic disease involving many organs. Fabry disease is due to a deficiency of alpha-galactosidase A caused by different usually "private" mutations. Enzyme replacement therapy (ERT) has been established, other therapeutic options are at an experimental stage. Classically, mechanical deposition of storage material in blood vessels was believed to lead to decreased blood supply with consecutive organ dysfunction. Recently, however, many secondary biochemical processes have been discussed to be involved in the pathogenesis of Fabry disease. For example, compromised energy metabolism has been found both in vitro and in vivo, altered lipid composition of membranes can lead to abnormalities in trafficking and sorting of rafts-associated proteins. We discuss the role of these secondary phenomena in the pathogenesis of Fabry disease.
法布里病,也称为安德森 - 法布里病,是一种X连锁溶酶体贮积症。临床表现高度可变,女性通常症状较轻。它是一种累及多个器官的多系统疾病。法布里病是由不同的通常为“私人”的突变导致α - 半乳糖苷酶A缺乏所致。酶替代疗法(ERT)已确立,其他治疗选择尚处于实验阶段。传统上,贮积物质在血管中的机械沉积被认为会导致血液供应减少,进而引发连续的器官功能障碍。然而,最近有许多继发的生化过程被认为与法布里病的发病机制有关。例如,在体外和体内均发现能量代谢受损,膜脂质组成的改变可导致筏相关蛋白运输和分选异常。我们讨论了这些继发现象在法布里病发病机制中的作用。